I had the opportunity to be in Chicago at the annual meeting of the American Urological Association (AUA) for the presentation of the Dendreon corporation successful clinical trial results for the first ever prostate cancer vaccine - PROVENGE.
PROVENGE trial results surpassed the survival benefits agreed to by the FDA as necessary for it to be approved as an available treatment. Provenge enhances the patient's own immune system to fight prostate cancer. The first IMMUNOTHERAPY treatment of this type for any cancer; a landmark medical breakthrough.
PHEN has worked with and supported Dendreon over the past few years in the company's quest to gain approval for PPROVENGE. Dr. Mitchell Gold, Dendreon president, presented at PHEN's 2006 African American Prostate Cancer Disparity Summit on Capitol Hill, and he is committed to making certain that Provenge is available to the men who suffer disproportionately from prostate cancer.
Thomas A Farrington PHEN President and Founder
My statement which was presented at the AUA press conference on PROVENGE, Tuesday, April 28th is below. Farrington Statement on Provenge at AUA Statement
Dendreon Provenge Data Release The official release on the Provenge clinical trials results. Provenge Data